Secretome Therapeutics To Advance Heart Therapies with Financing

Secretome Therapeutics, a biotechnology company focused on developing therapies derived from neonatal cardiac progenitor cells (nCPCs), announced the successful close of a funding round. The investment will support the initiation of clinical trials for the company’s lead candidate, STM-01, and accelerate its innovative pipeline. By the end of 2024, Secretome plans to launch two multiple-ascending dose Phase 1 trials for STM-01.

The first study to evaluate STM-01 in patients with heart failure with preserved ejection fraction. The second trial will evaluate STM-01's efficacy in patients with non-ischemic dilated cardiomyopathy.

Learn more